Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

RECRUITING

The APS Phenotyping Study

NCT06521502 · View on ClinicalTrials.gov ↗

Study Summary

The goal of the observational APS phenotyping study is to better understand risk factors, potential biomarkers, length and severity of illness, and recovery for adults with ARDS, pneumonia, and/ or sepsis. This study will also generate a biobank of specimens collected from these patients that will be available to investigators for future studies of ARDS, sepsis, and/or pneumonia.

Conditions Studied

Interventions

  • OTHER Blood collection
  • OTHER Urine Collection
  • OTHER Nasal, oral, and rectal swabs
  • OTHER Stool collection
  • OTHER Heat Moisture Exchange Filter collection

Study Locations (20)

California

  • Fresno Community Hospital and Medical Center — Fresno
  • Stanford University — Palo Alto
  • San Francisco General Hospital — San Francisco
  • University of California, San Francisco — San Francisco

Colorado

  • University of Colorado, Denver — Denver
  • Denver Health and Hospital Authority — Denver
  • National Jewish Health — Denver
  • UC Health Medical Center of the Rockies — Loveland

Illinois

  • Northwestern Memorial Hospital — Chicago
  • University of Chicago — Chicago

Tennessee

  • Meharry Medical College — Nashville
  • Vanderbilt University Medical Center — Nashville

Utah

  • Intermountain Medical Center — Murray
  • University of Utah — Salt Lake City

Maryland

  • Johns Hopkins Univeristy — Baltimore

Michigan

  • University of Michigan — Ann Arbor

Missouri

  • Washington University School of Medicine — St Louis

Trial Details

FieldValue
Enrollment Target 4,000 participants
Start Date 2024-07-25
Est. Completion 2029-04-30

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06521502

The ClinicalTrials.gov registry entry for NCT06521502 describes a study currently listed as recruiting. It is categorized as an unspecified phase, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 4,000 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Vanderbilt University Medical Center, which has 695 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 3 conditions, with Sepsis appearing as the primary indexed condition, and to 5 interventions — of which Blood collection is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT06521502 reports 20 study locations spanning 11 distinct geographic areas — top geographies include California, Colorado, Illinois. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT06521502 about?

NCT06521502 is a clinical study titled "The APS Phenotyping Study". The goal of the observational APS phenotyping study is to better understand risk factors, potential biomarkers, length and severity of illness, and recovery for adults with ARDS, pneumonia, and/ or sepsis. This study will also generate a biobank of specimens collected from these patients that will b...

What is the current status of trial NCT06521502?

This trial is currently recruiting. The enrollment target is 4,000 participants. The study started on 2024-07-25. Estimated completion is 2029-04-30.

What conditions does trial NCT06521502 study?

This clinical trial studies the following conditions: Sepsis, Pneumonia, ARDS. These conditions were identified from the trial registry and reflect the primary focus areas of the research.

What interventions are being tested in trial NCT06521502?

The interventions under investigation include: Blood collection (OTHER), Urine Collection (OTHER), Nasal, oral, and rectal swabs (OTHER), Stool collection (OTHER), Heat Moisture Exchange Filter collection (OTHER). Each intervention is being evaluated for safety and efficacy as part of this clinical study.

Who is sponsoring clinical trial NCT06521502?

This trial is sponsored by Vanderbilt University Medical Center, which has 695 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT06521502 being conducted?

This trial has 20 study locations across California, Colorado, Illinois, Maryland, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial